Click Therapeutics Acquires The Assets Of Better Therapeutics Focused On Metabolic Conditions

Click Therapeutics, Inc., announced plans to acquire the intellectual property (IP) assets of Better Therapeutics; both companies provide prescription digital therapeutics (PTDs). The assets include four PDTs, one of which is AspyreRx (BT-001), approved by U.S. Food and Drug Administration (FDA) for managing type 2 diabetes. Financial terms were not disclosed.

Click does not plan to self-commercialize AspyreRx as-is at this time. Instead, the company plans to adapt AspyreRx for treatment of obesity, and to benefit from Click’s AI-enabled platform as part of Click’s obesity digital therapeutic in development, CT-181. CT-181 . . .